Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.

Autor: Linhares Y; Baptist Health, Miami Cancer Institute, Miami, FL., Freytes CO; Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, San Antonio, TX., Cherry M; Department of Hematology Oncology/Medical Oncology, Atlantic Health System, Carol Simon Cancer Center, Morristown, NJ., Bachier C; Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, San Antonio, TX., Maris M; Department of Hematology/Oncology, Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, CO., Hoda D; Intermountain Healthcare, Loveland Clinic for Blood Cancer Therapy, Salt Lake City, UT., Varela JC; Advent Health, Orlando, FL., Bellomo C; New York Oncology Hematology, Albany, NY., Cross S; Virginia Oncology Associates, Norfolk, VA., Essell J; Oncology Hematology Care, Cincinnati, OH., Fanning S; Prisma Health, Greenville, SC., Terebelo H; Ascension Providence Hospital, Southfield, MI., Yimer H; Texas Oncology-Tyler, Tyler, TX., Courtright J; Texas Oncology, Medical City Dallas, Dallas, TX., Sharman JP; Willamette Valley Cancer Institute, Eugene, OR., Kostic A; Bristol Myers Squibb, Seattle, WA., Vedal M; Bristol Myers Squibb, Seattle, WA., Ogasawara K; Bristol Myers Squibb, Princeton, NJ., Avilion A; Bristol Myers Squibb, Seattle, WA., Espinola R; Bristol Myers Squibb, San Diego, CA., Yuan B; Bristol Myers Squibb, Princeton, NJ., Mattar B; Cancer Center of Kansas, Wichita, KS.

Publikováno v: Blood advances [Blood Adv] 2024 Dec 10; Vol. 8 (23), pp. 6114-6126.